Succinylcholine: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
== Contraindications ==
== Contraindications ==
#Hyperkalemia
#Preexisting hyperkalemia
#Burns >5d old
#Crush injury >5d old
#Severe infection >5d old
#Neuromuscular diseases, myopathies
#History of malignant hyperthermia


{| style="width: 500px" border="1" cellpadding="1" cellspacing="1"
Note: in MG theoretically need increased dose
|-
| '''Contraindication<br/>'''
| '''From-To'''
|-
| Known hyperK
| current
|-
| Massive burns >10% BSA
| >4dys-healed
|-
| Massive crush injuries
| >4dys-healed
|-
| Denervation^
| >4dys-6mo
|-
| Neuromuscular dz^^
| indefinite
|-
| Intra-abdominal sepsis
| >5dys-resolution
|-
| Increased ICP
| may use w/ defacic dose
|}


^CVA (in particular those with residual deficits), spinal cord injury
== Source  ==
Tintinalli


^^ALS, MS, skeletal muscle myopathies, cholinesterase def, h/o malignant hyperthermia
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.


*No evidence to support contraindication in penetrating eye injuries
[[Category:Drugs]]
*N.B. Myasthenia Gravis- theoretically need more succ to induce vs nondepolarizing agents which have a prolonged effect.
[[Category:Airway/Resus]]
*This is 2/2 to lack of post-synaptic receptors, i.e. succ cannot potentiate a reaction 2/2 too few receptors.
*Vs. it takes few "molecules" of roc/vec to block the few remaining functioning receptors.
*Overall, most practitioners tend to avoid succ in all patients with possible neuromuscular disease.
 
== Source ==
 
2/06 DONALDSON (Adapted from Rosen)
 
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.<br/>
 
[[Category:Drugs]] <br/>[[Category:Airway/Resus]]

Revision as of 22:12, 8 July 2011

Contraindications

  1. Hyperkalemia
  2. Preexisting hyperkalemia
  3. Burns >5d old
  4. Crush injury >5d old
  5. Severe infection >5d old
  6. Neuromuscular diseases, myopathies
  7. History of malignant hyperthermia

Note: in MG theoretically need increased dose

Source

Tintinalli

Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.